Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 14 Aug 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee (August 2023)
14 August 2023 - Additional documents are now available. ...
Posted by Michael Wonder on 12 Aug 2023
Jacobio Pharma announces breakthrough therapy designation from China CDE for KRAS G12C inhibitor glecirasib for the treatment of pancreatic cancer
7 August 2023 - Jacobio Pharma today announced that Jacobio's in house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation ...
Posted by Michael Wonder on 11 Aug 2023
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA mutated metastatic castration-resistant prostate cancer
11 August 2023 - Today, the FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech), ...
Posted by Michael Wonder on 11 Aug 2023
US FDA designates PYC's lead as a fast track development program
11 August 2023 - The Company is currently evaluating the safety/tolerability and efficacy of an investigational drug candidate with disease-modifying potential ...
Posted by Michael Wonder on 11 Aug 2023
PHARMAC proposes widening access to a brain cancer treatment to help reduce the impact of a discontinuation
11 August 2023 - PHARMAC is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type ...
Posted by Michael Wonder on 10 Aug 2023
Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...
Posted by Michael Wonder on 10 Aug 2023
Medicine costs to halve after Labor wins 60 day dispensing vote
10 August 2023 - More than six million Australians will have the cost of their medicines halved within weeks as ...
Posted by Michael Wonder on 10 Aug 2023
New COVID-19 vaccine and booster shots for this fall to be available by end of September
9 August 2023 - The first new COVID-19 vaccines updated for this fall season are now expected to be available by ...
Posted by Michael Wonder on 10 Aug 2023
US FDA accepts Astellas' sNDA for Cresemba (isavuconazonium sulphate) in children
10 August 2023 - Astellas announced that the US FDA has accepted the company's supplemental new drug application for Cresemba (isavuconazonium ...
Posted by Michael Wonder on 10 Aug 2023
FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma
10 August 2023 - On 9 August 2023, the FDA granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech) for adults with ...
Posted by Michael Wonder on 10 Aug 2023
How a controversial US drug policy could be harming cancer patients worldwide
9 August 2023 - The FDA’s accelerated approval process was designed to help people access life saving drugs. ...
Posted by Michael Wonder on 10 Aug 2023
PHARMAC’s Rare Disorders Advisory Committee makes new recommendations for funding
10 August 2023 - PHARMAC has published the record of the March Rare Disorders Advisory Committee meeting, sharing details on ...
Posted by Michael Wonder on 10 Aug 2023
Health Canada approves Alhemo (concizumab injection) for the treatment of patients living with haemophilia A with FVIII inhibitors
9 August 2023 - Health Canada has approved a new indication for Alhemo (concizumab injection) for the treatment of Canadian adolescent ...
Posted by Michael Wonder on 09 Aug 2023
Galera receives complete response letter from US FDA for avasopasem manganese
9 August 2023 - The Company remains committed to its goal of bringing avasopasem manganese to patients and intends to meet ...
Posted by Michael Wonder on 09 Aug 2023
FDA approves pralsetinib for non-small-cell lung cancer with RET gene fusions
9 August 2023 - Today, the FDA granted regular approval to pralsetinib (Gavreto, Genentech) for adult patients with metastatic rearranged ...